Relay Therapeutics Q4 net loss $0.45/sh; cash $781M; Phase 3 ReDiscover-2 trial mid-2025

Relay Therapeutics, Inc.

2024-FY EPS reported -$2.36 revenue$10,007,000

Net loss of $76.0M ($0.45/sh) in Q4 2024 vs $83.5M ($0.67/sh) in Q4 2023.
Cash, cash equivalents and investments of $781.3M at Dec 31, 2024, expected to fund operations into H2 2027.
Phase 3 ReDiscover-2 trial for RLY-2608 + fulvestrant in PI3Kα-mutated breast cancer to initiate mid-2025; 540 patients, PFS primary endpoint.
Phase 1b data showed 11.4-month median PFS and 39% ORR in 2L patients with PI3Kα-mutated HR+/HER2- advanced breast cancer.
Full year 2024 revenue $10.0M (down from $25.5M); net loss $337.7M ($2.36/sh).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.